Trial
NCT02067741
CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Swiss Cancer Institute
Collaborators
—
Condition
Metastatic Breast Adenocarcinoma
Intervention
CR1447
Why stopped
The SAKK board decided to prematurely end the life-long follow-up of the trial SAKK 21/12, as 90% of the patients have died.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-06-27